Scribe Therapeutics (SCTX) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- —
- Estimate
- -$1.03
- Surprise
- —
- Score today
- 4.5/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
Coverage in the report window
- ARK Invest Increases Holdings in Scribe Therapeutics — fiscal.ai, 2026-11-09
Where TrendMatrix's rating stands now
TrendMatrix currently rates SCTX Hold at 4.5/10; no pre/post engine snapshot brackets this report.
1 of the last 2 quarters beat the estimate.
What argues against it
- DATA_ISSUE: analyst_target_implausible (raw $57.00 vs price $16.86 — ratio 3.4×). Rejected, falling back to technical TP.
- Market cap $319M below $400M minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $16.86
- Price target
- $21.51
- Stop
- $15.68
- Upside to target
- +27.6%
Model outputs from TrendMatrix’s engine as of 2026-11-12 — shown for context, not personalized investment advice.
SCTX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $319.2M
- P/E (fwd)
- -4.7
- 52-week range
- $13.50–$39.60
- Off 52-week high
- 57.4%
- RSI (14)
- 45
- Volume vs avg
- 1.02×
- Score today
- 4.5/10